Skandinaviska Enskilda Banken (SEB)’s Intellia Therapeutics NTLA Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,223	Closed	-$555K	–	900
2023 Q4	$555K	Hold	18,223	–	–	﹤0.01%	769
2023 Q3	$576K	Hold	18,223	–	–	﹤0.01%	746
2023 Q2	$743K	Buy	18,223 +3,211	+21%	+$130K	﹤0.01%	742
2023 Q1	$559K	Sell	15,012 -688	-4%	-$27K	﹤0.01%	767
2022 Q4	$548K	Sell	15,700 -909	-5%	-$43.2K	﹤0.01%	724
2022 Q3	$929K	Buy	16,609 +4,327	+35%	+$268K	0.01%	695
2022 Q2	$636K	Hold	12,282	–	–	﹤0.01%	776
2022 Q1	$893K	Hold	12,282	–	–	0.01%	766
2021 Q4	$1.49M	Sell	12,282 -75	-0.6%	-$9.4K	0.01%	711
2021 Q3	$1.66M	Buy	+12,357	New	+$1.87M	0.01%	698
2021 Q1	–	Sell	-39,935	Closed	-$2.17M	–	1176
2020 Q4	$2.17M	Buy	39,935 +364	+0.9%	+$13.2K	0.01%	622
2020 Q3	$787K	Buy	39,571 +38,678	+4,331%	+$806K	0.01%	776
2020 Q2	$19K	Buy	+893	New	+$15.2K	﹤0.01%	1020

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s NTLA Position: Q1 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 18,223 shares — an estimated $555K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in NTLA in Q2 2020 and held it in 13 quarters. The position peaked at $2.17M in Q4 2020. 285 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

Skandinaviska Enskilda Banken (SEB) reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 18,223 Intellia Therapeutics shares in Q1 2024, an estimated $555K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Intellia Therapeutics in Q2 2020 and held it in 13 quarters.
Skandinaviska Enskilda Banken (SEB)'s Intellia Therapeutics position peaked at $2.17M in Q4 2020.
285 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2024, filed 13 May 2024.